After accounting
for expected patient attrition, we calculated that
we would need to enroll a total of 530 patients.
In agreement with the Food and Drug Administration,
the superiority of denervation over the
sham procedure was established by a margin of
5 mm Hg for the primary efficacy end point and
by a margin of 2 mm Hg for the secondary efficacy
end point.